Short answer
OPKO HEALTH, INC. (OPK) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). OPKO agreed to sell BioReference testing assets to Labcorp for $722 million cash at closing.
OPKO HEALTH, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- OPKO agreed to sell BioReference testing assets to Labcorp for $722 million cash at closing
- Additional consideration up to $150 million over 10 years tied to 4Kscore prostate test revenue
- Closing requires HSR antitrust clearance, with no financing condition, supporting transaction funding certainty
- Target closing deadline April 14, 2027, subject to extension by mutual agreement
- $28.88 million buyer termination fee if specified regulatory approvals fail
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OPKO HEALTH, INC. 8-K filings
Get the next OPK 8-K as it lands
Follow OPK for push alerts, or ask the research agent what this filing means.